EVALUATION OF THIOREDOXIN-1 SERUM MARKER FOR EARLY DIAGNOSIS OF PRIMARY BREAST CANCER
Background: Serum thioredoxin-1 (TRX-1) may be a useful biomarker for early diagnosis of breast cancer.
Subject and Methods: Thioredoxin -1 and cancer antigen15-3 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA) in 141 women: 55 had primary breast cancer, 35 with benign breast tumor and 51 were apparently healthy controls matched for age, waist circumference and body mass index. Diagnosis involved all women with breast mass who referred to the Histopathology Department, Duhok Specialized laboratory Center during the study period. Fine needle aspirate (FNA) cytology test was carried out first and then the findings were later on compared with histological results to confirm the diagnosis. Breast cancer women were further grouped into subtypes based on immunohistochemistry. The aim of this study was to assess the diagnostic capacity of thioredoxin-1 for primary breast cancer.
Results: Significantly higher Thioredoxine -1 and cancer antigen15-3 levels (p=0.001 and p=0.011 respectively) were found in primary breast cancer group compared to benign breast tumor group and healthy women. In breast cancer group, positive test was observed 2 times more likely than in benign breast tumor group as well in healthy women, with a sensitivity of 94.5%, specificity 72.1% and Receiver Operating Characteristics Curve ROC 0.872. Totally different and less significant values were observed for cancer antigen15-3, sensitivity 16.4%, specificity 93.0% and Receiver Operating Characteristics Curve ROC 0.352.
Conclusions: Elevated thioredoxin-1 level in conjunction with a high sensitivity and specificity may be strongly associated with primary breast cancer in women; this may indicate the needs for determining serum thioredoxin-1 as a screening test for early diagnosis of primary breast cancer
2. Shi Q, Gibson GE. Oxidative stress and transcriptional regulation in Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2007; 21(4):276-91.
3. Park B, Cha M, Kim I. Thioredoxin-1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses. BMC Res Notes. 2014; 7:7.
4. Welsh S, Bellamy W, Briehl M, Powis G. The redox protein thioredoxin-1 (TRX-1) increases hypoxia-inducible factor 1 alpha protein expression: TRX-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002; 62:5089-95.
5. Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin 1 and thioredoxin 1 in human breast carcinoma.Exp Clin Cancer Res. 2009; 28:93-101.
6. Cha MK, Park BJ, Kim II H. Thioredoxin 1 as a novel serum marker for human ovarian cancer. The FASEB journal 2012;26(I Supp 967.5).
7. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006; 16:420-6.
8. Reuter S, Gupta S, Chaturvedi M, Aggarwal B. Oxidative stress, inflammation, and cancer:: how are they linked?. Free Radic Biol Med. 2010; 49(11):1603-16.
9. Holmgren A, Lue J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease.Biochem Biophys Res Commun. 2010; 396(1):120-4.
10. Lincoln DT, Emadi FM, Tonissen KF, Clarke FM. The thioredoxin reductase system: over expression in human cancer. Anticancer Res. 2003;23: 2425-33.
11. Das KC, Das CK. Thioredoxin a single to oxygen quencher and hydroxyl radical scavenger: redox independent finctions. Biochem Biophys Res Commun. 2000; 277(2); 443-7.
12. Ueda S, Masutani H, Nakamura H, Tanaka T, Uneo M, Yodoi J. Redox control of cell death. Antioxid Redox Signal. 2002(3); 4:405-14.
13. Lillig CH, Holmgren A. Thioredoxin and related molecules: from biology to health and disease. Antioxid Redox Signal. 2007; 9(1):25-47.